Moleculin shares new investor presentation

Q: How is the Exhibit 99.1 presentation for MBRX treated under U.S. securities laws?

The Exhibit 99.1 presentation is being furnished, not filed, under a disclosure item. It is not considered filed under the Securities Exchange Act of 1934 and is not incorporated by reference into other Exchange Act or Securities Act filings unless specifically identified as such.

Moleculin Biotech, Inc. (MBRX) reported that on August 31, 2026 it is using a corporate presentation for its investor communications, which is included as Exhibit 99.1.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Moleculin Biotech, Inc. (MBRX) reported that on August 31, 2026 it is using a corporate presentation for its investor communications, which is included as Exhibit 99.1. The presentation is furnished under a disclosure item for informational purposes and is not deemed filed or incorporated into other securities law filings unless specifically stated.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

Emerging growth company, Securities Exchange Act of 1934, Securities Act of 1933

3 terms

Emerging growth company regulatory

"Emerging growth company Securities registered pursuant"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Securities Exchange Act of 1934 regulatory

"shall not be “filed” for the purpose of the Securities Exchange Act of 1934"

Securities Act of 1933 regulatory

"nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Moleculin Biotech, Inc. (MBRX) announce in its August 31, 2026 Form 8-K?

Moleculin Biotech, Inc. announced that it is using a corporate presentation for its corporate communications, attached as Exhibit 99.1, dated August 31, 2026. The presentation is provided for informational purposes under a disclosure item and is not deemed filed under the Exchange Act.

How is the Exhibit 99.1 presentation for MBRX treated under U.S. securities laws?

The Exhibit 99.1 presentation is being furnished, not filed, under a disclosure item. It is not considered filed under the Securities Exchange Act of 1934 and is not incorporated by reference into other Exchange Act or Securities Act filings unless specifically identified as such.

Does the August 31, 2026 Form 8-K for MBRX report any financial results or major transactions?

No. The August 31, 2026 Form 8-K for Moleculin Biotech, Inc. focuses on the use of a corporate presentation attached as Exhibit 99.1. It does not report financial results or major corporate transactions in the disclosed text.

Who signed the August 31, 2026 Form 8-K for Moleculin Biotech, Inc. (MBRX)?

The Form 8-K was signed on behalf of Moleculin Biotech, Inc. by Jonathan P. Foster, as the duly authorized representative of the registrant, dated August 31, 2026.

On which exchange is Moleculin Biotech, Inc. (MBRX) common stock listed?

Moleculin Biotech, Inc. common stock, par value $0.001 per share, trades under the symbol MBRX on The NASDAQ Stock Market LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/31/2026 - 05:15 PM EDT Accepted by SEC EDGAR 08/31/2026 - 05:15 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 31, 2026

MOLECULIN BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-37758	47-4671997
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

5300 Memorial Drive, Suite 950, Houston, TX 77007

(Address of principal executive offices and zip code)

(713) 300-5160

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol (s)	Name of each exchange on which registered
Common Stock, par value $.001 per share	MBRX	The NASDAQ Stock Market LLC

Item 7.01

Regulation FD Disclosure

On August 31, 2026, Moleculin Biotech, Inc. (the “Company”) is using the attached presentation for its corporate presentation posted on the Company’s website and is set forth as Exhibit 99.1 herein.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.

Description

99.1	Investor Presentation dated August 31, 2026

104	Cover page Interactive Data File (formatted as Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.